20
24 Half-year
Report
Creating the future in peptides
Editorial
“We made solid progress during H1 2024 and upgraded our 2024 full-year guidance. Our target for the mid-term is to double 2023 revenue by 2028.”
Peter Wilden
Chair of the Board of Directors
Juan José González
CEO
Highlights
Revenue
€m 135.0
+2.4%
EBITDA
€m 2.9
+22.3m
Capital expenditures
€m 20.5
15.2% of revenue
)
)
)
)
)